• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

St. Louis vaccine startup snags $3.6M. It expects more funding is on the way.
Omniose, a St. Louis startup focused on developing vaccines to prevent bacterial infections, has snagged $3.6 million in federal funding to advance one of its vaccine candidates. A $3.6 million grant from the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health (NIH) will be used by Omniose for research and development on a vaccine for Klebsiella pneumoniae, a bacteria that can cause an array of infections. For Omniose, the newly awarded grant continues …
Source: bizjournals.com Health Care:Biotechnology headlines - October 18, 2022 Category: Biotechnology Authors: Nathan Rubbelke Source Type: news

‘This Is Really Life or Death.’ For People With Disabilities, Coronavirus Is Making It Harder Than Ever to Receive Care
Jeiri Flores is normally a busy, upbeat 29-year-old. But amid the COVID-19 pandemic, her go-to thought has been dark. “If I get this,” she thinks, “I’m gonna die.” This is not an unfounded fear. Flores has cerebral palsy, uses a wheelchair and needs assistance with everyday tasks, including making food and getting dressed. Her disability means it’s tougher for her immune system to kick illnesses; she’s still recovering from a bout of pneumonia she had in January. So beating COVID-19 could easily mean a protracted battle and months in a hospital—a prospect that comes with a c...
Source: TIME: Health - April 24, 2020 Category: Consumer Health News Authors: Abigail Abrams Tags: Uncategorized COVID-19 Source Type: news

Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19. It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Wuhan Coronavirus Infections Have Now Surpassed the Official Number of SARS Cases in China
Chinese officials confirmed Wednesday that the number of people infected by a new form of coronavirus in the country has reached 5,974, a total that surpasses the official cases tallied on the mainland during an outbreak of severe acute respiratory syndrome (SARS) in 2002 and 2003. SARS infected 5,237 people in mainland China, and killed almost 800 people across the world. The new SARS-like form of coronavirus has killed 132 people in China. The disease, which is believed to have originated in a seafood market in the Chinese central city of Wuhan, has also spread to other countries, including the U.S., where five cases hav...
Source: TIME: Health - January 27, 2020 Category: Consumer Health News Authors: Sanya Mansoor and Amy Gunia Tags: Uncategorized China Infectious Disease onetime overnight Source Type: news

Functional Antibody Responses Following Allogeneic Stem Cell Transplantation for TP53 Mutant pre-B-ALL in a Patient With X-Linked Agammaglobulinemia
Discussion This case demonstrates successful cure of pre-B-ALL complicating XLA by alloSCT with restoration of B-cell development and functional antibody response. We are aware of only one previous case of pre-B-ALL in an XLA patient (21), which suggests that human BTK deficiency in itself does not predispose to pre-B-ALL. However, there are data to suggest that BTK may act as a tumor suppressor, and BTK deficiency may predispose to tumor development following a “second hit.” Mice with a genetic deficiency in Slp65, a gene encoding an adaptor protein that functions together with BTK, have a block in proge...
Source: Frontiers in Immunology - April 25, 2019 Category: Allergy & Immunology Source Type: research

Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome
This study was carried out after written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Stanford University and UCLA Institutional Review Boards. Author Contributions MB provided patient care and obtained IRB approval. RO prepared histology images. MB, TT, and RB designed the research. TT and LP conducted experiments and analyzed data. MB made the molecular model. MB and TT wrote the manuscript. Funding Funding for this work came from the Jeffrey Modell Foundation and from the NIH/NIGMS (R01 GM110482 to MB)....
Source: Frontiers in Immunology - April 11, 2019 Category: Allergy & Immunology Source Type: research

Why Flu Outbreaks Have Been the Worst in Nearly a Decade
The only thing worse than getting the flu is catching it after you’ve gotten a flu shot. It’s been a terrible year for outbreaks — the worst in almost a decade. Contributing to that is the high failure rate of this year’s vaccine. The current shot is just 25 percent effective against the H3N2 virus, this season’s most-often-identified strain by the Centers for Disease Control and Prevention. The experts say, with enough time and money, they can do a lot better. “There has to be a wholesale change to how we make the flu vaccine,” said Amesh Adalja, senior scholar at Johns Hopkins Ce...
Source: TIME: Science - February 28, 2018 Category: Science Authors: Bloomberg Tags: Uncategorized Bloomberg flu healthytime onetime Source Type: news

The World Is Not Ready for the Next Pandemic
Across China, the virus that could spark the next pandemic is already circulating. It’s a bird flu called H7N9, and true to its name, it mostly infects poultry. Lately, however, it’s started jumping from chickens to humans more readily–bad news, because the virus is a killer. During a recent spike, 88% of people infected got pneumonia, three-quarters ended up in intensive care with severe respiratory problems, and 41% died. What H7N9 can’t do–yet–is spread easily from person to person, but experts know that could change. The longer the virus spends in humans, the better the chance that i...
Source: TIME.com: Top Science and Health Stories - May 4, 2017 Category: Consumer Health News Authors: Bryan Walsh Tags: Uncategorized CDC Disease ebola Gates Foundation MERS outbreak pandemic Zika Source Type: news